CVS Health, a major U.S. healthcare company, has released its latest quarterly results. While the company's performance significantly exceeded market expectations and it raised its 2026 earnings guidance, a cautionary note on some core businesses for 2027 triggered market volatility, causing its shares to fall by approximately 6%.

Regarding its 2027 business outlook, CVS Health indicated that the application of new pricing models leading to contract restructuring, along with the contraction of market presence by some insurance clients, will result in a decline in membership next year for its pharmacy benefit management (PBM) unit, Caremark. Additionally, the company cited operational pressures related to the "340B Drug Pricing Program." With investor concerns already growing over the evolving financial model of PBMs, this business warning has further dampened market expectations.

Despite these localized business challenges, the company remains optimistic about continued performance improvements at its insurance subsidiary, Aetna. CVS Health CEO David Joyner emphasized that while the PBM business is currently under some pressure, the combined strengths of the group's overall operations are sufficient to offset these negative impacts. Joyner further noted that the current consensus for the company's adjusted earnings expectations in 2027 is already at a reasonable baseline level. The company maintains confidence in achieving its mid-term goal of double-digit earnings growth through 2028.